C. J. Venkatramani, PhD

Distinguished Scientist at Genentech

Speaker

C. J. Venkatramani is a Distinguished Scientist at Genentech USA with over 20 years of extensive experience in the pharmaceutical industry. He was the pivotal member of Genentech CMC team instrumental in taking gRED’s first small molecule Erivedge, from development to commercial. Erivedge is currently approved in several countries around the world for the treatment of advanced basal cell carcinoma (BCC). Over the past several years, CJ has focused his attention on the detailed characterization of peptides and new modalities. He is recognized in the scientific community for his pioneering contributions in multidimensional chromatography, addressing diluent-mobile phase incompatibility in one- and multidimensional chromatography and ultra-trace analysis of genotoxic impurities.